Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesFRA:NB3 +3.18%94 Cyclically Adjusted PS Ratio is 11.42 as of Jul. 23, 2026, which is 30% below its 10-year median of 16.20. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €172.38 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 751 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 92.01% on this metric.
The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:NB3'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.76 Med: 16.2 Max: 125.15
Current: 10.73
During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PS Ratio was 125.15. The lowest was 6.76. And the median was 16.20.
FRA:NB3's Cyclically Adjusted PS Ratio is ranked worse than 92.01% of 751
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs FRA:NB3: 10.73
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Neurocrine Biosciences's adjusted revenue per share data for the three months ended in Mar. 2026 was €6.814. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €13.65 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Neurocrine Biosciences (FRA:NB3) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Neurocrine Biosciences Cyclically Adjusted PS Ratio Related Terms
Neurocrine Biosciences Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Cyclically Adjusted PS Ratio Chart
FRA:NB3 vs VTRS, ELAN, UTHR: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PS Ratio falls into.
Neurocrine Biosciences Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 11.42 mean?
Neurocrine Biosciences (FRA:NB3) has a Cyclically Adjusted PS Ratio of 11.42 as of Jul. 23, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. This is 30% below median its historical median of 16.20. Over the past decade, Neurocrine Biosciences' Cyclically Adjusted PS Ratio has ranged from 6.76 to 125.15. According to the industry distribution chart, Neurocrine Biosciences ranks #691 out of 751 companies in the Drug Manufacturers industry, placing it in the top 92%.
Is Neurocrine Biosciences' Cyclically Adjusted PS Ratio too high?
Neurocrine Biosciences' current Cyclically Adjusted PS Ratio of 11.42 is 30% below median its 10-year median of 16.20. Over the past 10 years, this metric has ranged from a low of 6.76 to a high of 125.15. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 1.99. Neurocrine Biosciences' value of 11.42 is 473.9% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #691 out of 751 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cyclically Adjusted PS Ratio compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #691 out of 751 companies for Cyclically Adjusted PS Ratio. This places Neurocrine Biosciences in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.99. Neurocrine Biosciences' value of 11.42 is 473.9% above this benchmark. Historically, Neurocrine Biosciences' own Cyclically Adjusted PS Ratio has ranged from 6.76 to 125.15 over the past decade. While the company's 10-year median is 16.20 vs. the industry median of 1.99, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 1.99, based on 751 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Cyclically Adjusted PS Ratio of 11.42 is 473.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Cyclically Adjusted PS Ratio is 11.42, which is 30% below median its own 10-year median of 16.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €172.38, compared to a current price of €155.90 — trading 9.6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 11.42, which is 30% below median its 10-year median of 16.20 and 473.9% above the Drug Manufacturers industry median of 1.99. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Cyclically Adjusted PS Ratio is 11.42 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €155.90 is trading 9.6% below its estimated GF Value™ of €172.38.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:NB3:
Cyclically Adjusted PS Ratio: 11.42 (30% below median its 10-year median of 16.20)
GF Value™: €172.38 vs. price of €155.90 (9.6% below fair value)
Industry Position: 473.9% above the Drug Manufacturers median (#691 of 751)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
